News
Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...
Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, ...
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% in its stock price.
TipRanks on MSN22h
Pfizer’s New Study on Ponsegromab: A Potential Breakthrough in Pancreatic Cancer TreatmentPfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. has announced a new clinical study titled ‘A Phase 2b/3, ...
Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...
The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...
Pfizer Inc. will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology Annual Meeting, taking place May 30 to June 3 in ...
Pfizer Inc PFE, one of the world’s largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
Jun. 08, 2016 1:51 PM ET Pfizer Inc. (PFE) Stock SA Transcripts 151.29K Follower s Pfizer Inc. (NYSE: PFE) Analyst and Investor Call to Review Oncology Business and ASCO Data Presentations Call ...
Pfizer Inc. continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology Congress ...
Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion Proposed combination enhances Pfizer’s position as a leading company in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results